These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28271527)

  • 1. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
    Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.
    Li X; Liu R; Huang Z; Gurley EC; Wang X; Wang J; He H; Yang H; Lai G; Zhang L; Bajaj JS; White M; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2018 Aug; 68(2):599-615. PubMed ID: 29425397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.
    Liu R; Li X; Zhu W; Wang Y; Zhao D; Wang X; Gurley EC; Liang G; Chen W; Lai G; Pandak WM; Robert Lippman H; Bajaj JS; Hylemon PB; Zhou H
    Hepatology; 2019 Oct; 70(4):1317-1335. PubMed ID: 30985008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Wang Y; Aoki H; Yang J; Peng K; Liu R; Li X; Qiang X; Sun L; Gurley EC; Lai G; Zhang L; Liang G; Nagahashi M; Takabe K; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2017 Jun; 65(6):2005-2018. PubMed ID: 28120434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation.
    Li M; Zhou Y; Zhu H; Xu LM; Ping J
    J Integr Med; 2024 Mar; 22(2):188-198. PubMed ID: 38472011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
    Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
    Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡.
    McDaniel K; Meng F; Wu N; Sato K; Venter J; Bernuzzi F; Invernizzi P; Zhou T; Kyritsi K; Wan Y; Huang Q; Onori P; Francis H; Gaudio E; Glaser S; Alpini G
    Hepatology; 2017 Feb; 65(2):544-559. PubMed ID: 27639079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
    Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
    Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia.
    Xiao Y; Liu R; Li X; Gurley EC; Hylemon PB; Lu Y; Zhou H; Cai W
    Hepatology; 2019 Nov; 70(5):1658-1673. PubMed ID: 31063660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis.
    Svinka J; Pflügler S; Mair M; Marschall HU; Hengstler JG; Stiedl P; Poli V; Casanova E; Timelthaler G; Sibilia M; Eferl R
    J Mol Med (Berl); 2017 Jan; 95(1):109-117. PubMed ID: 27568040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocyte-Derived Exosomal lncRNA H19 Promotes Macrophage Activation and Hepatic Inflammation under Cholestatic Conditions.
    Li X; Liu R; Wang Y; Zhu W; Zhao D; Wang X; Yang H; Gurley EC; Chen W; Hylemon PB; Zhou H
    Cells; 2020 Jan; 9(1):. PubMed ID: 31940841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockout of the Tachykinin Receptor 1 in the Mdr2
    Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
    Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule.
    Song Y; Liu C; Liu X; Trottier J; Beaudoin M; Zhang L; Pope C; Peng G; Barbier O; Zhong X; Li L; Wang L
    Hepatology; 2017 Oct; 66(4):1183-1196. PubMed ID: 28407375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
    Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
    FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Wan Y; Meng F; Wu N; Zhou T; Venter J; Francis H; Kennedy L; Glaser T; Bernuzzi F; Invernizzi P; Glaser S; Huang Q; Alpini G
    Hepatology; 2017 Aug; 66(2):528-541. PubMed ID: 28256736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Kyritsi K; Chen L; O'Brien A; Francis H; Hein TW; Venter J; Wu N; Ceci L; Zhou T; Zawieja D; Gashev AA; Meng F; Invernizzi P; Fabris L; Wu C; Skill NJ; Saxena R; Liangpunsakul S; Alpini G; Glaser SS
    Hepatology; 2020 Mar; 71(3):990-1008. PubMed ID: 31344280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
    Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
    Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of hepatic stellate cell and fibroblast-derived LOXL1 attenuates BDL- and
    Yan X; Zhang N; Wei L; Zhang W; Huang T; Li W; Chen W; Yang A; You H
    Am J Physiol Gastrointest Liver Physiol; 2023 Dec; 325(6):G608-G621. PubMed ID: 37873581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma.
    Gamaev L; Mizrahi L; Friehmann T; Rosenberg N; Pappo O; Olam D; Zeira E; Bahar Halpern K; Caruso S; Zucman-Rossi J; Axelrod JH; Galun E; Goldenberg DS
    Oncogene; 2021 Jan; 40(1):127-139. PubMed ID: 33093654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of neutrophil extracellular trap components ameliorates cholestatic liver disease in Mdr2 (Abcb4) knockout mice.
    Hintermann E; Tondello C; Fuchs S; Bayer M; Pfeilschifter JM; Taubert R; Mollenhauer M; Elferink RPJO; Manns MP; Christen U
    J Autoimmun; 2024 Jun; 146():103229. PubMed ID: 38653165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.